Gossamer Bio, Inc.
GOSS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GOSS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GOSS
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing seralutinib, an inhaled therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), with Phase 3 trials ongoing and cash runway into early 2027.
Key risk: Cash runway limited
BioSniper Score
Based on 5 of 6 signals
Market Cap
$83.2M
Cash Runway
4.6 moLead Asset
seralutinib (Phase 3)Next Catalyst
Phase3_Topline · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials · 2 catalysts for Gossamer Bio, Inc..
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing seralutinib, an inhaled therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), with Phase 3 trials ongoing and cash runway into early 2027.
- Cash and equivalents of $41.1M as of 2026-06-30 [sec].
- Total revenue of $9.2M and net income of $16.9M for the period ended 2026-06-30 [sec].
- Accumulated deficit of $1,485.6M as of March 31, 2026 [sec_mda · as of 2026-05-15].
- Phase 3 PROSERA study in PAH initiated in Q4 2023; topline data expected in February 2026 [sec_mda · as of 2025-05-15].
- Cash runway expected to fund operations into the first quarter of 2027 [sec_mda · as of 2026-08-13].
What works
- Seralutinib has completed a Phase 2 TORREY study with positive topline results in PAH patients [sec_mda · as of 2025-05-15].
- The company has initiated a global registrational Phase 3 PROSERA study in PAH and expects to report topline data in February 2026 [sec_mda · as of 2025-05-15].
- Gossamer Bio is also advancing seralutinib for PH-ILD, with plans to activate first clinical sites for the Phase 3 SERANATA study in Q4 2025 [sec_mda · as of 2025-05-15].
- The company has assembled a deeply experienced team of industry veterans and key opinion leaders [sec_mda · as of 2025-05-15].
What to weigh
- Gossamer Bio has incurred significant operating losses since inception, with a net loss of $46.7M for Q1 2026 and an accumulated deficit of $1,485.6M as of March 31, 2026 [sec_mda · as of 2026-05-15].
- Cash and equivalents have declined sharply from $136.9M at year-end 2025 to $41.1M as of June 30, 2026, with runway only into Q1 2027 [sec_mda · as of 2026-03-17] [sec].
- The company faces substantial uncertainty regarding FDA feedback and the regulatory path for seralutinib, which could affect spending and timelines [sec_mda · as of 2026-03-17].
- Future capital requirements depend on many factors including clinical trial costs, regulatory review, and manufacturing, and the company may need additional financing [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Cash runway into Q1 2027
“we believe that our existing cash, cash equivalents and marketable securities, will be sufficient to fund our operations into the first quarter of 2027”
SEC MD&A · August 13, 2026
Accumulated deficit of $1,485.6M as of March 31, 2026
“As of March 31, 2026, we had an accumulated deficit of $1,485.6 million.”
SEC MD&A · May 15, 2026
Phase 3 PROSERA topline data expected February 2026
“We expect to report topline data from the PROSERA study in February 2026.”
SEC MD&A · May 15, 2025
Positive Phase 2 TORREY results
“we announced positive topline results from the Phase 2 TORREY Study in PAH patients.”
SEC MD&A · May 15, 2025
Catalyst timeline
- 2026-12-01 · Phase3_Topline — An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inh — Topline results from an open-label extension study of seralutinib will provide long-term safety and efficacy data.
- 2028-12-01 · Phase3_Topline · seralutinib (GB002) — A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of — Topline results from the pivotal Phase 3 PROSERA study will evaluate seralutinib's efficacy and safety in PAH.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash of $41.1M as of 2026-06-30 expected to fund operations only into Q1 2027 [sec] [sec_mda · as of 2026-08-13].
- Regulatory uncertainty — FDA feedback on seralutinib path is pending; official minutes may differ from meeting views [sec · filed 2026-07-27].
- Clinical trial costs — Costs of Phase 3 trials and regulatory approval are uncertain and could exceed current estimates [sec_mda · as of 2026-08-13].
- Accumulated deficit — Accumulated deficit of $1,485.6M as of March 31, 2026, with ongoing net losses [sec_mda · as of 2026-05-15].
What to watch
- Topline data from the Phase 3 PROSERA study in PAH expected in February 2026 [sec_mda · as of 2025-05-15].
- FDA feedback on a potential path forward for seralutinib, which may affect commercial planning and spending [sec_mda · as of 2026-03-17].
- Activation of first clinical sites for the Phase 3 SERANATA study in PH-ILD in Q4 2025 [sec_mda · as of 2025-05-15].
- Cash burn rate and any need for additional financing given runway into Q1 2027 [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Gossamer Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Gossamer Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
4.6 months
OCF -$39M · Net income $17M
Lead: Phase 3
2 candidates
2 upcoming, next in ~93d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
187
Total value held
$50.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 18,789,186 | $6.2M |
| blackrock, inc. | 16,826,695 | $5.5M |
| aqr capital management llc | 10,126,897 | $3.3M |
| arch venture management, llc | 8,055,916 | $2.6M |
| samsara biocapital, llc | 7,222,559 | $2.4M |
| balyasny asset management l.p. | 5,922,298 | $1.9M |
| 683 capital management, llc | 5,000,000 | $1.6M |
| hhlr advisors, ltd. | 4,974,041 | $1.6M |
| geode capital management, llc | 4,939,691 | $1.6M |
| qube research & technologies ltd | 4,917,763 | $1.6M |
Showing top 10 of 187 institutional holders of Gossamer Bio, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 18.2%
- Days to cover
- 3.6
- Shares short
- 40,196,107
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GOSS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Gossamer Bio, Inc.?
Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing seralutinib, an inhaled therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), with Phase 3 trials ongoing and cash runway into early 2027.
What is Gossamer Bio, Inc.'s lead drug candidate?
Gossamer Bio, Inc.'s most advanced tracked candidate is seralutinib (Phase 3) for Pulmonary Arterial Hypertension.
What is Gossamer Bio, Inc.'s next catalyst?
Gossamer Bio, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inh" — expected December 1, 2026.
Who is the CEO of Gossamer Bio, Inc.?
Mr. Faheem Hasnain is the chief executive officer of Gossamer Bio, Inc. (GOSS).
Where is Gossamer Bio, Inc. headquartered?
Gossamer Bio, Inc. (GOSS) is headquartered in San Diego, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.